Anterior Segment Company Showcase - Encore Vision at OIS@AAO 2016. Presenter: Bill Burns, President & CEO Powered by: Healthegy For more ophthalmology innovation Visit us at www.ois.net

1. CONFIDENTIAL
1
EV06 Ophthalmic Solution (Lipoic Acid Choline Ester)
Topical Treatment For Presbyopia
Results from a Phase I – II Clinical Study
Post Treatment Follow-up Study Progress
Encore Vision, Inc.
Bill Burns
Chief Executive Officer

2. CONFIDENTIAL
What is EV06 - How Does it Work?
• EV06 (Lipoic Acid Choline Ester,
1.5%) is a prodrug
Choline Lipoic Acid
Lipoic Acid Choline Ester• EV06 penetrates cornea -
metabolized into Choline &
Lipoic Acid, two naturally
occurring substances
Dihydrolipoic Acid
• Enzymes within lens fiber
cells chemically reduce
Lipoic Acid to active form
Dihydrolipoic Acid
(DHLA)
• DHLA reduces disulfide
bonds – restores lens
microfluidics

3. CONFIDENTIAL
EV06 Phase I – II Clinical Study Design
3
• Prospective, randomized, double-masked, placebo-controlled multicenter Phase I/II study
• 75 subjects with hyperopia, myopia, or emmetropia and a diagnosis of presbyopia
randomized 2:1 (EV06 or Placebo) BID
• Study visits, Days -7, 0, 1, 8, 15, 31, 61, 91
Key inclusion criteria:
•45-55 years of age
•DCNVA worse than 20/40 in each eye
•BCDVA (Best Corrected Distance Visual Acuity) of 20/20 or better in each eye
•Difference of ≤ 0.50 D between manifest refraction spherical equivalent and cycloplegic
refraction spherical equivalent

4. CONFIDENTIAL
EV06 Phase I – II Clinical Study Design - Safety
Safety = Non-dominant eye dosed initially for one
week to confirm safety and tolerance

5. CONFIDENTIAL
• Comfort
• Day 1 and prior to each visit
• 0 – 10 scale
• Compliance
• Diary
• Office visit questions
Measurements and Study Details
5
• Four Study Sites across US
• Safety Assessments included:
• Change in General Ocular Health
• Best Corrected Distance Visual Acuity
• IOP
• Slit lamp findings(lens, anterior & posterior
capsule, nucleus)
• Fundus findings
• Adverse events

6. CONFIDENTIAL
Baseline Patient Demographics
6
Placebo
N=25
EV06
N=50
Age (SD)
Gender
Males
Race
51.4 (± 3.0)
5 (20%)
50.1 (± 3.2)
17 (34%)
White
Females 20 (80%) 33 (66%)
Black
18 (72%) 35 (70%)
7 (28%) 15 (30%)
Ethnicity
Hispanic or Latino
Not Hispanic or Latino
5 (20%) 16 (32%)
20 (80%) 34 (68%)
Baseline DCNVA (OU)* 0.408 (± 0.12) 0.397 (± 0.10)
Baseline DCNVA (study eye)*0.500 (± 0.10) 0.507 (± 0.11)Table 14.1.2
Table 14.2.1.1
*Mean LogMAR (SD)
(0.05 LogMAR = 20/63 Snellen)
(0.40 LogMAR = 20/50 Snellen)

7. CONFIDENTIAL
EV06 is Safe and Well Tolerated
7
Placebo
N=25
EV06
N=50
Subject Discontinuations
Ocular
Any subject with at least one
ocular related TEAE
2 (8%)
0 (0%)
1 (2%)
0 (0%)
0 (0%) 2 (4%)
Ocular related TEAE
Asthenopia
Blepharitis
Conjunctival hyperaemia
Eye irritation
Eye pruritus
Foreign body sensation in eyes
Ocular hyperaemia
Vision blurred
0 (0%) 1 (2%)
2 (8%) 0 (0%)
0 (0%) 2 (4%)
0 (0%) 2 (4%)
0 (0%) 2 (4%)
0 (0%) 1 (2%)
0 (0%) 1 (2%)
EV-C-002
Table 14.3.2.1.3
Table 14.3.2.4.2
TEAE = Treatment Emergent Adverse Event, defined as any event not present prior to the initiation of the treatments or any event already present that worsens
in either intensity or frequency following exposure to the treatments
TESAE =Treatment Emergent Serious Adverse Event
TESAE (all organs)
3 (12%) 8 (16%)
Instillation irritation 0 (0%) 2 (4%)
Instillation pain 1 (4%) 3 (6%)
Isolated Events
Not persistent

8. CONFIDENTIAL
EV-C-002 Study Efficacy Endpoints
8
1. Change in DCNVA (LogMAR) from Day 1 to Day 91 of the Study Eye (Non-
dominant eye)
2. Study subjects with a gain ≥10 letters from Day 1 to Day 91 in DCNVA of the Study
Eye (Non-dominant eye)
3. Change in Bilateral (OU) DCNVA (LogMAR) from Day 1 to Day 91
DCNVA = distance corrected near visual acuity
EV-C-002

9. CONFIDENTIAL
P-values two-sample t-test, EV06 vs. Placebo. Error bars represent SEM
0.00
0.05
0.10
0.15
0.20
0.25
ChangeinDCNVA(logMAR)fromday0
(absolutechange)
EV06 Shows Improved Bilateral Near Vision Over Time
Change in DCNVA (LogMAR) from Baseline OU
Day 8 Day 15 Day 31 Day 61 Day 91
p=0.007
p=0.001
p=0.024
p=0.001
p=0.004
9
2.5
2.0
1.0
0.5
1.5
NumberofSnellenlinesincreased
N 25 50 24 50 23 49 23 49 23 49
Table 14.2.1.1
Table 14.2.1.6.3, non-LOCF. Change in DCNVA, per N for each day. EV-C-002

10. CONFIDENTIAL
EV06 Improves Percent of Subjects that Gain Bilateral Near Vision
Subjects Showing a Gain of ≥10 letters in DCNVA (OU)
10
0
10
20
30
40
50
60
Day 8 Day 15 Day 31 Day 61 Day 91
%ofSubjects
Placebo
EV06
p = 0.001
p = 0.004
p = 0.025
p = 0.040
p = 0.021
p values for Fisher’s Exact Test EV06 vs. Placebo
Table 14.2.1.9.3, non-LOCF. % calc. per N for each day.
N 25 50 24 50 23 49 23 49 23 49
EV-C-002

11. CONFIDENTIAL
EV06 Improves Bilateral Near Vision
Distance Corrected Near Vision Acuity (DCNVA) OU Day 91
11
Placebo
N=23
EV06 1.5%
N=49
Percent of Subjects with
Improvement in DCNVA
1 line (≥ 0.10 LogMAR)
2 lines (≥ 0.20 LogMAR)
3 lines (≥ 0.30 LogMAR)
4 lines (≥ 0.40 LogMAR)
4%
52%
22%
0%
0%
0%
84%
53%
22%
12%
p = 0.009
p = 0.021
p = 0.013
p = 0.167
Any Loss in DCNVA (≥0.10)
No Change in DCNVA (-0.09 to 0.09) 44% 16% p = 0.020
p = 0.319
p values for Fisher’s Exact Test EV06 vs. Placebo
Per Protocol
EV-C-002. Table 14.2.1.4.3. non-LOCF. % calc. per N Day 91: Placebo N/23; EV06
N/49

12. CONFIDENTIAL
EV06 Shows Improved Bilateral Near Vision Over Time
DCNVA Snellen scores (OU) Day 1 & Day 91
12
0 0
8
22
36
22
12
0
12
24 24
22
8 8
0 0
-5
0
5
10
15
20
25
30
35
40
20/20 20/25 20/32 20/40 20/50 20/63 20/80 20/100
%Subjects
Day 1 EV06 Day 91 EV06
Shift (Improvement)
in Snellen Scores
Table 14.2.1.1
20/5420/28

13. CONFIDENTIAL
iTrace: Ray Tracing Aberrometry
13
• Sends 256 rapid,
sequential laser beams
into eye in under ¼
second
• Unique FORWARD Ray
Tracing Detects where
each thin beam lands
on macula
• Automatically calculates
ocular refraction and
HO aberrations

14. CONFIDENTIAL
How to Interpret Refraction Maps
14
iTrace software uses the Zernike
calculations to produce refractive
power maps
Refraction Maps give us total ocular
refraction in diopters on a point-by-
point basis across pupil
Displays refraction maps in 3-D to see
depth of focus (DOF)
Red or hot colors in the maps =
myopic refractive powers
Green = emmetropia
Blue or cool colors = hyperopic
refractive powers

15. Control subject on 90 day Placebo -3.00D near
stimulus – no improvement
Day 90
Near
Vision
Day 90 Far Vision Difference

16. 53-yo patient day 1 of EV06 treatment with
20/30 near at -3.00D target
Day 1 Near Vision Day 1 Far Vision Difference

17. 53 yo Patient after 45 day EV06 treatment with
20-30 near at -3D target
Day 45 Near VisionDay 1 Far Vision Difference

18. 53-yo patient after 90 day EV06 treatment with
20/20 near at -3.00D target
Day 90 Near VisionDay 90 Far Vision Difference

19. 53 yo treated with binocular refraction maps
showing great binocular near vision on 3-D

20. CONFIDENTIAL
iTrace Conclusions
20
 Significant HOA induced changes on order of -3.00D in central
lens refractive power due to change in lens optical properties
(index of refraction and curvature) provides increase depth of
field over 90 days with treatment of EV06
 With OU treatment binocular near vision is provided with
benefit of natural stereopsis over current monovision
techniques

21. CONFIDENTIAL
EV-C-003 Post-Treatment Study (Days 150 and 210)
21
Assessments
• Efficacy:
• Identical to EV-C-002
• Safety:
• Identical to EV-C-002
Status
• Enrollment:
• EV06: 32 subjects (approx)
• Placebo: 16 subjects (approx)
• Last Subject, Last Visit:
• October, 2016

22. CONFIDENTIAL
EV06 Conclusions
22
 EV06 Ophthalmic Solution
 Near Vision can be recovered
 Restores natural bilateral near vision in presbyopic subjects
84% of presbyopic subjects with 20/40 OU near vision or
greater when treated with EV06 vs. 52% in placebo*
53% of presbyopic subjects with ≥0.2 LogMAR change in
OU near vision when treated with EV06 vs. 22% in placebo^
 Acceptable safety and tolerability profile
No Change in Best Corrected Distance Visual Acuity
No Change in Pupil Diameter
No Change in IOP

23. CONFIDENTIAL
Next Steps
23EV06 Phase 2 B Dose Ranging Study Q1 ’17
Target Initiate Phase 3 Pivotal Studies Q2 ‘18
Long-term safety
Longer duration of treatment

24. CONFIDENTIAL
Thank You
24
Advisors
Jerry Cagle, PhD
Dan Durrie, MD
Adrian Glasser, PhD
David Gooden, PhD
Marjorie Lou, PhD
Jayne Weiss, MD
Encore Vision Team
Kathryn Crawford, PhD
Shikha Barman, PhD
Judy Gordon, DVM
Jerry Stein, PhD
Stella Robertson, PhD
William Garner, PhD
Margaret Garner, PhD
Dennis Dean, PhD
Travis Whitfill, MPH
Lexitas Pharma Services, Inc
Regulatory Professionals, Inc (RPI)
Board of Directors
Peter Bennett
William Burns
Adrienne Graves, PhD
John Hunkeler, MD
Les Kreis
Richard Lindstrom, MD
Ed Tyler (Chairman)